Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02906371
Other study ID # 16CT022, 825445
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 2016
Est. completion date June 30, 2021

Study information

Verified date June 2021
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated cytokine release syndrome safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with high versus low pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).


Description:

The duration of active protocol intervention is approximately 12-15 months from the screening visit. The protocol will require approximately 12-18 months to complete enrollment.Approximately 39 enrolled patients to reach at least 35 infused patients, with the ultimate goal of 15 patients in the high tumor burden cohort (Cohort A). Inclusion criteria are designed to include pediatric patients aged 1-24 years with CD19 expressing relapsed/refractory B-cell acute lymphoblastic leukemia (ALL).Tocilizumab will be given once to high disease burden patients, and then the patients will be managed for CRS as per the standard algorithm (including subsequent tocilizumab, if needed). Two cohorts are defined based upon pre-infusion high versus low tumor burden; with the high tumor burden cohort (high risk of severe CRS) to receive earlier administration of tocilizumab for CRS management and the low tumor burden cohort (low risk of severe CRS) to receive standard timing of tocilizumab for CRS


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date June 30, 2021
Est. primary completion date March 11, 2020
Accepts healthy volunteers No
Gender All
Age group 1 Year to 24 Years
Eligibility Inclusion Criteria: 1. Signed informed consent form must be obtained prior to any study procedure. Labs, marrows or other procedures obtained during routine clinical care may be used for eligibility if obtained within the protocol required windows. 2. Relapsed or refractory B-cell ALL: 1. 2nd or greater marrow relapse OR 2. CNS relapse OR 3. Any relapse after allogeneic hematopoietic stem cell (SCT) transplant and = 4 months from SCT at enrollment OR 4. Any relapse after CAR-modified T cell therapy OR 5. Refractory disease defined as having not achieved an MRD-negative CR after = 2 chemotherapy regimens/cycles (1 cycle for relapsed patients) OR 6. Patients with Ph+ ALL are eligible if they are intolerant to or have failed tyrosine kinase inhibitor therapy OR 7. Ineligible for allogeneic SCT because of: - Comorbid disease - Other contraindications to allogeneic SCT conditioning regimen - Lack of suitable donor - Prior SCT - Declines allogeneic SCT as the therapeutic option after documented discussion, with expected outcomes, about the role of SCT with a bone marrow transplant (BMT) physician not part of the study team 8. Patients with B lymphoblastic lymphoma will be eligible if they meet one of the above criteria OR: - 2nd or greater relapse OR - Refractory disease defined as having not achieved CR with frontline therapy or after 1 cycle of reinduction therapy for relapsed patients 9. Patients with prior or current history of CNS3 disease will be eligible if CNS disease is responsive to therapy (at infusion, must meet criteria in Section 5.3) 3. Documentation of CD19 tumor expression in bone marrow, peripheral blood, CSF, or tumor tissue by flow cytometry at relapse (or a recent sample in the case of refractory disease). If the patient has received CD19-directed therapy (i.e. blinatumomab), then the flow cytometry should be obtained after this therapy to show CD19 expression. 4. Adequate organ function defined as: 1. A serum creatinine based on age/gender as follows: Maximum Serum Creatinine (mg/dL) Age Male Female - 1 to < 2 years 0.6 0.6 - 2 to < 6 years 0.8 0.8 - 6 to < 10 years 1.0 1.0 - 10 to < 13 years 1.2 1.2 - 13 to < 16 years 1.5 1.4 - = 16 years 1.7 1.4 2. ALT =500 U/L 3. Bilirubin =2.0 mg/dl 4. Must have a minimum level of pulmonary reserve defined as = Grade 1 dyspnea, pulse oximetry > 92% on room air; DLCO = 40% (corrected for anemia) if PFTs are clinically appropriate as determined by the treating investigator 5. Left Ventricular Shortening Fraction (LVSF) = 28% or Ejection Fraction (LVEF) = 40% confirmed by ECHO, or adequate ventricular function documented by a scan or a cardiologist. 5. Evidence of disease by standard morphologic or MRD criteria. A clinical marrow or tissue biopsy showing disease may be performed at enrollment or within 12 weeks of enrollment. Presence of marrow disease not required for CNS disease or lymphoblastic lymphoma patients. 6. Age 1-29 years. Patients ages 24-29 years are eligible if their original leukemia diagnosis was prior to age 21. 7. Adequate performance status (Lansky or Karnofsky score =50). 8. Subjects of reproductive potential must agree to use acceptable birth control methods, as described in protocol Section 4.3. Exclusion Criteria: 1. Active hepatitis B or active hepatitis C. 2. HIV Infection. 3. Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy. 5. CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity. 6. Pregnant or nursing (lactating) women. 8. Uncontrolled active infection.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tocilizumab
Patients with = 40% blasts in the bone marrow at pre-infusion will be enrolled in the early tocilizumab cohort and will follow early CRS treatment algorithm.
Tocilizumab
Patients with ? 40% blasts in the bone marrow at pre-infusion (~ Day -5 to -1) will follow the standard CRS Rx algorithm
Biological:
CART 19
CART-19 cells transduced with a lentiviral vector to express either anti-CD19? scFv TCR?:41BB, administered by i.v. injection using an intra-patient dose escalation approach: 10% on day 0, 30% on day 1 with a total dose goal of ~1.5 x107 - 5 x109 (~3x105 - 1x108/kg) T cells.

Locations

Country Name City State
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
University of Pennsylvania Children's Hospital of Philadelphia

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other CART19 cellular kinetics Peak plasma concentration (Cmax) of CART19 cellular kinetic from day -1 to year 1
Other Number of days in ICU from day 0 through year one.
Other Frequency of major medical interventions from day 0 through year one.
Other CART19 cellular kinetics Area under the plasma concentration versus time curve (AUC) from day -1 through year 1
Primary the frequency of grade 4 CRS Frequency of CRS grade 4 from day 1 to 1 year
Secondary tumor response Frequency of CR with minimal residual disease negative bone marrow at day 28 and duration of remission day 28
See also
  Status Clinical Trial Phase
Recruiting NCT05043571 - CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia Phase 1
Recruiting NCT05495035 - Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL Phase 1
Completed NCT01411267 - AC220 for Children With Relapsed/Refractory ALL or AML Phase 1
Completed NCT00991133 - A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL) Phase 1
Active, not recruiting NCT05440409 - CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
Completed NCT01861002 - A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML Phase 1
Terminated NCT01100658 - Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors N/A
Completed NCT01321346 - A Study Of Panobinostat In Children With Refractory Hematologic Malignancies Phase 1
Completed NCT01896752 - Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL N/A
Completed NCT01614197 - A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma Phase 1
Recruiting NCT05429905 - Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia Phase 1/Phase 2
Recruiting NCT02879643 - Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL Phase 1
Recruiting NCT03022747 - Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol Phase 2
Active, not recruiting NCT03817320 - PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Phase 1/Phase 2
Terminated NCT05611086 - N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia Phase 4
Terminated NCT01186328 - EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) Phase 1
Recruiting NCT05038696 - ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. Phase 1

External Links